SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2.22 |
| Enterprise Value ($M) | -10.86 |
| Book Value ($M) | 9.15 |
| Book Value / Share | 3.09 |
| Price / Book | 0.24 |
| NCAV ($M) | 8.99 |
| NCAV / Share | 3.04 |
| Price / NCAV | 0.25 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -3.68 |
| Return on Assets (ROA) | -0.80 |
| Return on Equity (ROE) | -0.93 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.39 |
| Current Ratio | 2.39 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 15.45 |
| Assets | 15.60 |
| Liabilities | 6.45 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 4.85 | -0.11 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 19,358 | 120,238 | 16.10 | |
| 111,063 | 374,165 | 29.68 | |
| 176,977 | 620,230 | 28.53 | |
| 3,549 | 21,339 | 16.63 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| OCX – OncoCyte Corporation | OKYO – OKYO Pharma Limited |
| ONCO – Onconetix, Inc. | ONCY – Oncolytics Biotech Inc. |
| ONVO – Organovo Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io